In this episode:

00:58 – Tell us a bit about your professional journey and why you are exhibiting?
02:35 – Why did you build TraxQM your risk-based QMS?
04:16 – What does TraxQM do?
07:14 – Important aspects of TraxQM?
09:19 – Event presence

In this episode:

01:15 – Can you explain the importance of creating a culture of sustainability across laboratories?
03:12 – What challenges does AstraZeneca face in sustaining laboratories, and how are they addressing them?
05:06 – Can you describe the focus area of AstraZeneca’s Green Labs sustainability initiatives?
07:36 – How does AstraZeneca engage their employees in sustainability initiatives?
09:46 – How does the “My Green Lab” certification contribute to creating a culture of sustainability among laboratory colleagues?
11:47 – Event presence

In this episode:

01:10 – What is PACE technology and how is it enabling zero waste, zero error, just-in-time pharmaceutical manufacturing and supply?
04:35 – How does PACE work?
12:17 – How is PACE improving manufacturing accuracy and reduced waste and rejects? It’s well documented that speeding up manufacture has a higher risk of more errors?
14:32 – How is PACE unique to current ways of working?
19:32 – What does PACE mean for digitalisation?
22:02 – Event presence

In this episode:

00:56 – What does Pharma 4.0 mean to you?
02:16 – In what ways will digital technologies transform pharma R&D and manufacturing?
04:48 – Is anything stopping us from implementing everything you have described?
06:09 – You are in CMC Regulatory Affairs – what’s your perspective on the regulatory dossiers – how will they change?
07:48 – Is there a global angle to this – are all countries the same?
09:01 – Event presence

In this episode:

00:53 – Please introduce yourself and OnSite Energy and what you do.
05:25 – Can you give an overview of energy and decarbonisation trends you see?
10:19 – What are the primary issues you see in pharmaceutical facillities?
12:13 – Can you give two examples of your work in the pharmaceutical industry?
17:04 – What are the applications for innovative technologies and integration with renewable energy?
19:26 – What are the main takeaways?
20:59 – Event presence

In this episode:

01:08 – What is a nanoparticle and where do they come from?
02:17 – What is the difference between a nanoparticle and nanotechnology? Why are they perceived differently by consumers and NGO’s?
03:45 – What is the current legislation on nanoparticles that impact the pharmaceutical industry? Is there any new legislation on the horizon that will impact pharma?
05:11 – What sort of risk do nanoparticles pose to humans? How is this assessed by regulatory and safety of bodies?
06:49 – Why should this topic concern the pharmaceutical industry?
09:02 – Event presence

In this episode:

01:24 – What are the key drivers behind the extraordinary timelines and costs in the biopharmaceutical industry?
04:19 – What innovative approaches are leading companies implementing to compress timelines and reduce costs?
07:54 – Can you share insights from your work in microbiomes, and how you see therapeutics evolving over the next decade?
11:39 – Event presence

In this episode:

00:47 – Please tell us a bit about yourself
01:41 – What are the key benefits of conducting effective self-inspections?
02:52 – What are the common gaps between self-inspection and regulatory findings and how can organisations address them?
04:14 – Can you share practical tips for preparing and conducting a successful self-inspection audit?
06:14 – How can organisations ensure their self-inspection programs are continuously improving and remain effective?
07:29 – Can you give background on EPiC and how you can help companies ensure their self-inspections are adding value?
08:30 – Event presence

In this episode:

00:58 – What was your first involvement with AI?
03:48 – It is hard to distinguish between the fact and fiction about AI – please give three top facts.
06:34 – Based on your Keynote session about staying relevant in the AI era, please give a practical example that can be applied?
10:30 – What will you be covering in your Workshop – “An Introduction to AI for Pharma Professionals & Parents – in 30 minutes”?
14:45 – Do you have any concerns relating to AI in Pharma?
19:56 – Event presence

In this episode:

01:00 – What is the role of Radiopharmaceuticals in Healthcare treatment?
02:15 – How do the logistics fit into the cycle?
04:18 – How does transporting Radiopharmaceuticals differ – what are the critical factors?
05:40 – How does Life Couriers differentiate to support the Radiopharmaceuticals sector?
07:38 – What are the potential complications of deliveries and how do you negate these?
10:15 – Event presence

In this episode:

01:06 – You will be talking about “Do Engineers, Operations, and Quality speak the same language?” What do you mean by this?
03:14 – Is your presentation therefore about specific terminology?
05:07 – This all sounds interesting, but also a bit theoretical. Will you provide actual examples, use case studies?
07:17 – Event presence

In this episode:

01:50 – How do you think the transition to net zero is going in pharmaceuticals?
02:46 – Considering environmental threats overall, isn’t pharmaceutical manufacturing insignificant?
04:50 – Won’t making pharmaceuticals more sustainably make healthcare more expensive?
07:06 – Don’t we just need to wait for greener drugs to come through the pipeline?
09:05 – What can people in pharmaceutical manufacturing and distribution do to accelerate the transition?
10:36 – Event presence

In this episode:

01:05 – What is lyophilization?
01:54 – How is it used in pharmaceutical technology?
02:22 – What are the benefits of freeze-drying?
03:32 – What equipment is required?
04:12 – What is the focus of the study that you will present?
05:12 – Which analytical methods are used?
06:32 – Event presence

In this episode:

00:57 – Tell me about the HDA – the organisation’s role and objectives?
03:18 – What are your members’ priorities at the moment?
06:09 – What are the future challenges to the pharmaceutical distribution sector?
07:52 – What will you be covering in your presentation at Distributing Pharmaceuticals?
09:20 – Event presence

In this episode:

01:01 – What was the inspiration for the topic of your presentation?
01:58 – Why do you think so many companies find themselves in the situations you describe?
03:50 – What are some of the consequences you have seen as a result of companies allowing backlogs to develop or not dealing with backlogs effectively?
05:10 – You mentioned prioritisation. Companies have so many conflicting priorities and limited resources. What advice can you give to help them determine where to focus their efforts?
06:20 – What do you think is the one major thing that companies can do today that will help drive improvement?
07:22 – Event presence

In this episode:

00:56 – What is your background and why are you going to Making Pharmaceuticals and Distributing Pharmaceuticals?
02:18 – What is the key topic that you are going to be talking about in your Keynote presentation?
03:26 – What are the key changes that you think will help to transform the POTC industry in the coming years?
06:21 – What do you anticipate the participants will gain from attending your presentation?
10:02 – Event presence

In this episode:

00:54 – Can you explain the role of a specialty chemical distributor in the pharmaceutical industry, and introduce Surfachem?
01:38 – You have talked about intelligent distribution – what does that mean?
02:46 – You are launching a diabetes-focused specialty at this year’s event – can you tell us more about this initiative? What are the unique ingredients or solutions that specifically address the needs of diabetes-related formulations?
04:27 – How does one ensure the quality, reliability, and compliance of ingredients for such critical healthcare applications? And how do you adapt to evolving regulatory landscapes in the pharmaceutical industry, ensuring it remains a reliable partner?
07:31 – Looking ahead what are Surfachem’s goals for growing its pharmaceutical services, particularly in specilalised fields like diabetes, and how do you see Surfachem contributing to improved health outcomes for patients through it’s ingredient distribution?

In this episode:

01:06 – What is EXCiPACT Certification?
03:30 – How can I get certified?
05:03 – How can I use my supplier’s EXCiPACT Certification?
06:55 – Why can I trust the EXCiPACT Certification?
10:57 – Is is approved?
13:40 – EXCiPACT’s presence at the event

In this episode:

00:53 – How did AIT start its journey to become a specialist in shipping pharmaceuticals?
02:44 – What are the biggest challenges in handling and shipping pharmaceuticals and how can they be overcome?
05:46 – What is the value to logistics companies of having their own healthcare licenses issued by the MHRA?
07:29 – What predictions does AIT have relating to the future shape of the pharma industry?
09:15 – What subject are you presenting at the conference?

In this episode:

0:57 – Why do you come to the event?
02:43 – What will you be doing over the two days?
03:58 – What makes leadership skills so critical in the pharmaceutical industry compared to other industries?
05:32 – Why do you believe leadership skills are more important now than ever?
07:12 – What leadership skills are most in demand for leaders in the pharmaceutical sector today?

In this episode:

1:19 – How has Brexit and the implementation of the Windsor Framework impacted the supply and distribution of pharmaceuticals into Northern Ireland?
2:49 – As a consequence of Brexit are there any other controls in the flow of trade between Great Britain and Northern Ireland that affects the Pharmaceutical and Healthcare Sector?
4:35 – How is Trans-Bridge meeting the ESG expectations of global pharmaceutical suppliers?
6:32 – Do you see any other opportunities to expand your service offerings to other offshore UK islands?

In this episode:

00:56 – You have presented at Making Pharmaceuticals since the second year on the topic of QPs and related topics – what is your professional background?
01:40 – What is a QP and an RPi – and what are the differences?
03:20 – What changes have you seen in the role of a QP?
04:33 – Tell us more about your presentation for 2025 on the roles of QP and RPi in supply chain management.

In this episode:

1:04 – How long have you worked in the pharma industry?
2:08 – What are the major changes you have seen over the years?
3:39 – Over the past 60 years small molecules have been the focus, will the future be more biologics pharma?
5:37 – How do you see sustainability playing a role in the pharma industry?
8:20 – Event presence

In this episode:

00:58 – What will you be talking about at MakingPharmaceuticals?
01:20 – What is a checklist?
02:15 – Why is a checklist important when auditing?
02:29 – Are there any disadvantages of checklists?
03:14 – What are the advantages of using checklists?

In this episode:

01:50 – Why is safety such an important topic in the making and distributing of pharmaceuticals?
03:15 – What does a robust safety culture look like?
05:52 – What does “psychological safety” mean?
09:00 – What is the role in safety for leaders in making and distributing pharmaceuticals?